OBJECTIVES: To evaluate the @entity137 and outcomes of the allogeneic transplantation of peripheral blood hematopoietic stem-cells with low intensity conditioning (mini-alo Bone Marrow transplantation-BMT) in @entity1358 refractory to at least one line of systemic treatment. METHODS: From 30 @entity1 submitted to the Sant Pau's Hospital for immunotherapy between 1/2001 and 1/2003, six @entity1 finally underwent mini-alo BMT within a clinical trial. Conditioning: @entity3118 : 30 minute i.v. infusion of 13 mg/m2 on days -9, -8, -7, -6 and -5. Busulfan: 1 mg/kg (real weight) q 6 hours, PO on days -6, -5, and -4 (4 doses per day on days -6 and -5, and 2 doses only on day -4, total number of doses 10). RESULTS: Two @entity1 achieved partial response, one @entity1 stabilized disease, and two @entity1 had progression on days +30 and +60. Therefore, 2/3 @entity1 surviving more than six months achieved partial response. One @entity1 died on day +30 after acute hepatic @entity2132 . Complete chimerism was demonstrated in all @entity1 . CONCLUSIONS: The mimni-alo BMT is feasible in @entity1 with @entity1358 and provides objective responses, although its efficacy should be confirmed by phase III clinical trials.

[Allogeneic transplantation of peripheral blood hematopoietic stem-cells with low intensity conditioning for the treatment of a metastatic XXXX . Preliminary results after two years of follow-up].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['Fludarabine'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['metastatic renal cell carcinoma'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['graft-versus-host disease']
@entity1358 :: (MESH:D002292,Disease) :: ['clear cell carcinoma']
